Cargando…

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

The results of haploidentical stem cell transplantation (haploHCT) for patients with acute lymphoblastic leukemia (ALL) transplanted in active disease remain largely unknown. We retrospectively analyzed adult patients with R/R ALL who underwent haploHCT or matched sibling donor (MSD-HCT) as a first...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagler, Arnon, Labopin, Myriam, Swoboda, Ryszard, Pioltelli, Pietro, Arat, Mutlu, Yakoub-Agha, Ibrahim, Kulagin, Alexander, Maria Raiola, Anna, Ozdogu, Hakan, Risitano, Antonio, Nur Ozkurt, Zubeyde, Sanz, Jaime, Brissot, Eolia, Zina, Peric, Giebel, Sebastian, Ciceri, Fabio, Mohty, Mohamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575736/ https://www.ncbi.nlm.nih.gov/pubmed/36258924 http://dx.doi.org/10.1097/HS9.0000000000000790

Ejemplares similares

Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia
por: Nagler, Arnon, et al.
Publicado: (2020)

Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Nagler, Arnon, et al.
Publicado: (2021)

Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Lee, Catherine J, et al.
Publicado: (2017)

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
por: Brissot, Eolia, et al.
Publicado: (2019)

P1371: GRAFT-VERSUS-HOST DISEASE OFFERS NO GRAFT-VERSUS-LEUKEMIA ADVANTAGE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLO-IDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
por: Shimoni, A., et al.
Publicado: (2022)

Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
por: Nagler, Arnon, et al.
Publicado: (2023)

Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
por: Nagler, Arnon, et al.
Publicado: (2023)

Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
por: Santoro, Nicole, et al.
Publicado: (2017)

A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
por: Piemontese, Simona, et al.
Publicado: (2017)

Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
por: Brissot, Eolia, et al.
Publicado: (2020)

New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
por: Mohty, Razan, et al.
Publicado: (2023)

Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT
por: Canaani, Jonathan, et al.
Publicado: (2017)

CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission
por: Kharfan-Dabaja, Mohamed A., et al.
Publicado: (2022)

Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Giebel, Sebastian, et al.
Publicado: (2019)

Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT
por: Saraceni, Francesco, et al.
Publicado: (2023)

Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years—a registry-based study by the Acute Leukemia Working Party of the EBMT
por: Hirschbühl, Klaus, et al.
Publicado: (2023)

Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT
por: Sanz, Jaime, et al.
Publicado: (2020)

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT
por: Piemontese, Simona, et al.
Publicado: (2019)

Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT
por: Sanz, Jaime, et al.
Publicado: (2021)

Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
por: Hermans, Sjoerd J. F., et al.
Publicado: (2023)

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors
por: Brissot, Eolia, et al.
Publicado: (2020)

Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
por: Filippini Velázquez, Giuliano, et al.
Publicado: (2023)

GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
por: Baron, Frédéric, et al.
Publicado: (2023)

Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT
por: Munker, Reinhold, et al.
Publicado: (2017)

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
por: Pavlů, Jiří, et al.
Publicado: (2019)

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT
por: Santoro, Nicole, et al.
Publicado: (2018)

Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study
por: Shouval, Roni, et al.
Publicado: (2016)

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Salvatore, Dalila, et al.
Publicado: (2018)

Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Bazarbachi, Ali, et al.
Publicado: (2020)

Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT
por: Rubio, Marie T., et al.
Publicado: (2016)

Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues
por: Jaiswal, Sarita Rani, et al.
Publicado: (2016)

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT
por: Gilleece, Maria H., et al.
Publicado: (2021)

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
por: Schmid, Christoph, et al.
Publicado: (2021)

Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Ye, Yishan, et al.
Publicado: (2023)

Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine
por: Giannotti, Federica, et al.
Publicado: (2018)

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
por: Brissot, Eolia, et al.
Publicado: (2017)

Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia
por: Schmaelter, Ann-Kristin, et al.
Publicado: (2020)

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party
por: Rubio, Marie Thérèse, et al.
Publicado: (2017)

Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Halaburda, Kazimierz, et al.
Publicado: (2020)

Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT
por: Spyridonidis, Alexandros, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1rj9h8f0ogu80cqkfnhnb6f2rl